Inosine Pranobex
Important Information for the Patient.
This medication should always be used exactly as described in this patient information leaflet or as advised by a doctor or pharmacist.
Neotac is an antiviral and immunostimulant medication (it stimulates the activity of the immune system).
Indications: as a supportive treatment in patients with reduced immunity, in cases of recurrent upper respiratory tract infections.
If there is no improvement or the patient feels worse after 5-14 days, they should consult their doctor.
Before starting to use Neotac, the patient should discuss it with their doctor or pharmacist:
and will monitor kidney and liver function.
If symptoms of an allergic reaction are observed, such as rash, itching, difficulty breathing, swelling of the face, lips, throat, or tongue. In such cases, treatment should be stopped immediately and a doctor consulted.
Neotac should not be used in children under 1 year of age.
The patient should inform their doctor or pharmacist about all medications they are currently taking or have recently taken, as well as any medications they plan to use. They should especially inform their doctor about the medications listed below, as they may interact with Neotac:
In these cases, the doctor may decide whether to use Neotac.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medication.
Neotac should not be used during pregnancy and breastfeeding, unless the doctor advises otherwise.
It is unlikely that Neotac will affect the ability to drive and use machines.
(E 216).
Sucrose
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medication.
1 ml of the medication contains 0.650 g of sucrose. This should be taken into account in patients with diabetes.
Methyl parahydroxybenzoate and propyl parahydroxybenzoate
The medication may cause allergic reactions (possible late reactions).
This medication should always be used exactly as described in the patient information leaflet or as advised by a doctor or pharmacist. If in doubt, the patient should consult their doctor or pharmacist.
The medication should be taken orally.
Recommended dose
The dose is determined based on the patient's body weight. The daily dose should be divided into equal single doses taken several times a day.
To measure the recommended volume, the measuring cup provided with the packaging should be used.
Adults, including the elderly (over 65 years):
1 ml of syrup per kg of body weight per day (usually 60 ml of syrup per day in 3 or 4 divided doses). The maximum daily dose is 80 ml of syrup, which is 4 g of inosine pranobex per day.
Children over 1 year of age
1 ml of syrup per kg of body weight per day. The medication should be administered in 3 equal divided doses per day, according to the following table:
10–14 kg
5 ml
15–20 kg
5 to 7.5 ml
21–30 kg
7.5 to 10 ml
31–40 kg
10 to 15 ml
41–50 kg
15 to 17.5 ml
To measure the recommended volume, the measuring cup provided with the packaging (10 ml capacity, with 2.5 ml graduations) should be used.
Duration of Treatment
Depending on the patient's health status, treatment usually lasts from 5 to 14 days. After the symptoms have subsided, the medication is usually continued for another 1 to 2 days.
No cases of overdose have been reported. If there are any doubts, the patient should immediately consult their doctor.
If a dose is missed, it should be taken as soon as possible, unless it is almost time for the next dose. A double dose should not be taken to make up for a missed dose.
If treatment is stopped, the expected therapeutic effect may not be achieved, or the symptoms of the disease may worsen. If there are any further doubts about using this medication, the patient should consult their doctor or pharmacist.
Like all medications, Neotac can cause side effects, although not everyone will experience them.
Any medication can cause an allergic reaction, but severe allergic reactions to Neotac are very rare.
The patient should immediately consult their doctorif they experience any of the following symptoms:
Very common (more than 1 in 10 patients):
increased uric acid levels in the blood, increased uric acid levels in the urine.
Common (less than 1 in 10 patients):
nausea, vomiting, discomfort in the upper abdomen, increased liver enzyme activity, increased urea levels in the blood, itching, rash, headache, dizziness, fatigue (weakness), malaise (weakness).
Uncommon (less than 1 in 100 patients):
diarrhea, constipation, nervousness, sleepiness or difficulty sleeping (insomnia), increased urine output (polyuria).
Frequency not known (cannot be estimated from available data):
abdominal pain, angioedema (swelling of the face, lips, eyelids, or throat, which may cause difficulty breathing), hives, allergic reaction, anaphylactic reaction (allergic reaction affecting the whole body), flushing (redness of the skin).
If the patient experiences any side effects, including those not listed in this leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to:
Department for Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Aleje Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medication.
The medication should be stored out of sight and reach of children.
The medication should not be used after the expiry date stated on the packaging after "Expiry Date" or "EXP". The expiry date refers to the last day of the month stated.
Store in a temperature below 25°C.
The shelf life after opening the bottle is 5 months.
Medications should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
The active substance of Neotac is inosine pranobex (a complex containing inosine and 4-acetamidobenzoic acid 2-hydroxypropyldimethylammonium in a molar ratio of 1:3).
One ml of syrup contains 50 mg of inosine pranobex.
The other ingredients are: sucrose, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), glycerol, lemon flavor [containing, among others, propylene glycol (E 1520) and ethanol], purified water.
Neotac is a syrup with a citrus fruit smell.
The packaging of Neotac is an orange glass bottle containing 180 ml of syrup, closed with a PP (outer layer) and LDPE (inner layer) cap. The packaging also includes a 10 ml PP measuring cup with 2.5 ml graduations.
TACTICA Pharmaceuticals Sp. z o. o.
ul. Bankowa 4
44-100 Gliwice
phone: +48 889 388 538
[Logo of the marketing authorization holder]
ABC Farmaceutici S.P.A.
Canton Moretti 29,
Loc. S. Bernardo
10090 Ivrea (TO) Italy
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.